Copyright © Inderes 2011 - present. All rights reserved.

OrganoClick

1.66 SEK

+3.75 %

Less than 1K followers

ORGC

First North Stockholm

Chemicals

Basic Materials

+3.75 %
-2.64 %
-5.14 %
-2.35 %
-8.54 %
-25.88 %
-57.57 %
-84.41 %
-76.68 %

OrganoClick operates in environmental technology. The company offers specialized solutions based on fiber-based materials, where the company develops, produces and markets functional fiber chemistry. The products are mainly used in water-repellent fabrics and primarily in wood treatment to protect against fungal decay and fire. The company was founded in 2006 and has its headquarters in Täby.

Read more
Market cap
182.61M SEK
Turnover
123.49K SEK
Revenue
106.19M
EBIT %
-29.73 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/5
2026

Interim report Q1'26

20/5
2026

General meeting '26

17/7
2026

Interim report Q2'26

ShowingAll content types
Third party research

OrganoClick: Soft end to 2025, better setup into 2026 - ABG

* Q4 sales -16% vs. ABGSCe, miss in GC&MP and FW * NW&FT showing positive signs; we see a return to growth in '26e * We cut '26e-'27e sales by 7% on weaker-than-expected report Q4 results OrganoClick reported Q4 sales of SEK 18m (-16% vs. ABGSCe) and...

OrganoClick
Third party research

OrganoClick: Positive sales in binders, weak elsewhere - ABG

* Q4 sales SEK 18m (-14% y-o-y), -16% vs. ABGSCe * EBIT adj. of SEK -11m (vs. ABGSCe -5.5m) * NW&FT showing signs of improvement, weaker GC&MP and FW Q4 results Sales came in at SEK 18m (-16% vs. ABGSCe 22m), -14% y-o-y (-14% org.). NW&FT increased sales...

OrganoClick

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

OrganoClick: Expecting to see early signs of recovery - ABG

* Q4e sales SEK 22m (21m), EBIT adj. SEK -5.5m (-6.9m) * We expect NW&FT to start showing early signs of recovery * Trading at '26e-'27e EV/Sales 2.2x-2.0x Q4 expectations For Q4, we estimate sales of SEK 22m, +2% y-o-y and -3% q-o-q (NW&FT: +7% y-o-...

OrganoClick
Third party research

OrganoClick: Cost savings to cushion volume headwinds - ABG

* Q3 soft, lower volumes from two major customers* We cut '26e-'27e sales and EBIT by 6% and SEK 6m, respectively* Expect volume recovery to take longer than initially projectedQ3 challenging, but cost savings aheadQ3 sales were lower than expected at...

OrganoClick
Third party research

OrganoClick: Challenging Q3, but cost-cutting underway - ABG

* Q3 sales SEK 22m (-22% y-o-y), EBIT -6.4m (vs. ABGSCe -4.9m)* Lower volumes from two major customers due to timing effects* Cost savings program of ~SEK 14m announcedQ3 resultsSales came in lower than expected at SEK 22m (-18% vs. ABGSCe 27m), -22%...

OrganoClick
Third party research

OrganoClick: Expect gains in GCMP, pressure elsewhere - ABG

* Report out on 5 November* Q3e sales of SEK 27m (29m), EBIT SEK -5m (-3m)* GC&MP the bright spot, other segments under pressureQ3 expectationsQ3 marks the beginning of the second half of the year, which is typically weaker for OrganoClick (particularly...

OrganoClick
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.